GENE ONLINE|News &
Opinion
Blog

2021-08-16| ChinaSpecial

Innovent Announces Gastric Cancer Trial Win for Tyvyt, Reveals Plans for Another China Approval

by Rajaneesh K. Gopinath
Share To
Earlier today, Innovent announced positive outcomes from a gastric cancer trial that evaluated Tyvyt (sintilimab injection) in combination with chemotherapy. Interim analysis shows that the combo therapy met the primary endpoint of overall survival in patients.

Approved originally for treating relapsed or refractory classical Hodgkin’s lymphoma in China, Tyvyt had recently bagged its third NMPA approval. The immunotherapy, a fully human IgG4 anti-PD-1 monoclonal antibody, was developed by Innovent in collaboration with Eli Lilly.

GO Prime with only $1.49 now

LATEST
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
Partnership to Manufacture Antibiotic to Combat Antimicrobial Resistance
2023-09-25
Revolutionary Technology Aims to Detect and Prevent Dementia and Mental Illness
2023-09-22
Connecting Global Biotech, Largest Biotech Event of Thailand Takes Center Stage
2023-09-22
BIOHK2023: A Place Where Biotechnology Meets Financial Economics
2023-09-21
Connecting the Dots: TCELS Leads the Way for Thailand’s Life Sciences and Healthcare Innovations
2023-09-20
Deceptive Health Advice on TikTok Raises Concerns About Gynecologic Cancer Misinformation
2023-09-20
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top